Asian Pacific Journal of Cancer Prevention

  • 제13권5호
  • /
  • Pages.1963-1969
  • /
  • 2012
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

The Metabolic Syndrome and Risk Factors for Biliary Tract Cancer: A Case-control Study in China

  • Wu, Qiao (Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College) ;
  • He, Xiao-Dong (Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College) ;
  • Yu, Lan (Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College) ;
  • Liu, Wei (Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College) ;
  • Tao, Lian-Yuan (Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College)
  • 발행 : 2012.05.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objectives: Recent data show that the metabolic syndrome may play a role in several cancers, but the etiology for biliary tract cancer is incompletely defined. The present aim was to evaluate risk factors for biliary tract cancer in China. Methods: A case-control study in which cases were biliary tract cancer patients referred to Peking Union Medical College Hospital (PUMCH). Controls were randomly selected from an existing database of healthy individuals at the Health Screening Center of PUMCH. Data on the metabolic syndrome, liver diseases, family history, and history of diabetes and hypertension were collected by retrospective review of the patients' records and health examination reports or by interview. Results: A total of 281 patients (102 intrahepatic cholangiocarcinoma (ICC), 86 extrahepatic cholangiocarcinoma (ECC) and 93 gallbladder carcinoma (GC)) and 835 age- and sex-matched controls were enrolled. $HBsAg^+/anti-HBc^+$ (P=0.002), history of diabetes (P=0.000), cholelithiasis (P=0.000), TC (P=0.003), and HDL (P=0.000) were significantly related to ICC. Cholelithiasis (P=0.000), Tri (P=0.001), LDL (P=0.000), diabetes (P=0.000), Apo A (P=0.000) and Apo B (P=0.012) were significantly associated with ECC. Diabetes (P=0.017), cholelithiasis (P=0.000) and Apo A (P=0.000) were strongly inversely correlated with GC. Conclusion: Cholelithiasis, HBV infection and metabolic symptoms may be potential risk factors for the development of biliary tract cancer.

키워드

참고문헌

  1. Alvaro D, Barbaro B, Franchitto A, et al (2006). Estrogens and insulin-like growth factor 1 modulate neoplastic cell growth in human cholangiocarcinoma. Am J Pathol, 169, 877-88. https://doi.org/10.2353/ajpath.2006.050464
  2. Benitez S, Camacho M, Bancells C, et al (2006). Wide proinflammatory effect of electronegative low-density lipoprotein on human endothelial cells assayed by a protein array. Biochim Biophys Acta, 1761, 1014-21. https://doi.org/10.1016/j.bbalip.2006.03.020
  3. Ben-Menachem T(2007). Risk factors for cholangiocarcinoma. Europ J Gastroenterol Hepatol, 19, 615-7. https://doi.org/10.1097/MEG.0b013e328224b935
  4. Ben Q, Cai Q, Li Z, et al (2011). The relationship between new-onset diabetes mellitus and pancreatic cancer risk: a case-control study. Eur J Cancer, 47, 248-54. https://doi.org/10.1016/j.ejca.2010.07.010
  5. Cai HH, Sun YM, Bai JF, et al (2008). Relationship between the GH-IGFs axis and the proliferation of bile duct cancer cell line QBC939 in vitro. Hepatobiliary Pancreat Dis Int, 7, 76-81.
  6. Cardinale V, Semeraro R, Torrice A, et al (2010). Intra-hepatic and extra-hepatic cholangiocarcinoma: New insight into epidemiology and risk factors. World J Gastrointest Oncol, 2, 407-16. https://doi.org/10.4251/wjgo.v2.i11.407
  7. El-Serag HB, Hampel H, Javadi F (2006). The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol, 4, 369-80. https://doi.org/10.1016/j.cgh.2005.12.007
  8. Federico A, Morgillo F, Tuccillo C, et al (2007). Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer, 121, 2381-6. https://doi.org/10.1002/ijc.23192
  9. Feig DI, Sowers LC, Loeb LA (1994). Reverse chemical mutagenesis: identification of the mutagenic lesions resulting from reactive oxygen species-mediated damage to DNA. Proc Natl Acad Sci USA, 91, 6609-13. https://doi.org/10.1073/pnas.91.14.6609
  10. Feingold KR, Soued M, Adi S, et al (1990). Tumor necrosis factor-increased hepatic very-low-density lipoprotein production and increased serum triglyceride levels in diabetic rats. Diabetes, 39, 1569-74. https://doi.org/10.2337/diabetes.39.12.1569
  11. Festi D, Dormi A, Capodicasa S, et al (2008). Incidence of gallstone disease in Italy: results from a multicenter, population-based Italian study (the MICOL project). World J Gastroenterol, 14, 5282-9. https://doi.org/10.3748/wjg.14.5282
  12. Furberg AS, Veierod MB, Wilsgaard T, et al (2004). Serum highdensity lipoprotein cholesterol, metabolic profile, and breast cancer risk. J Natl Cancer Inst, 96, 1152-60. https://doi.org/10.1093/jnci/djh216
  13. Gatto M, Bragazzi MC, Semeraro R, et al (2010). Cholangiocarcinoma: update and future perspectives. Dig Liver Dis, 42, 253-60. https://doi.org/10.1016/j.dld.2009.12.008
  14. Giovannucci E (2001). Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr, 131, S3109-20. https://doi.org/10.1093/jn/131.11.3109S
  15. Hammarsten J, Hogstedt B (2004). Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press, 13, 47-55. https://doi.org/10.1080/08037050310025735
  16. Hardardottir I, Grunfeld C, Feingold KR(1994). Effects of endotoxin and cytokines on lipid metabolism. Curr Opin Lipidol, 5, 207-15. https://doi.org/10.1097/00041433-199405030-00008
  17. Hou PC (1956). The relationship between primary carcinoma of the liver and infestation with Clonorchis sinensis. J Pathol Bacteriol, 72, 239-46. https://doi.org/10.1002/path.1700720130
  18. Hsing AW, Gao YT, Devesa SS, et al (1998). Rising incidence of biliary tract cancers in Shanghai, China. Int J Cancer, 75, 368-70. https://doi.org/10.1002/(SICI)1097-0215(19980130)75:3<368::AID-IJC7>3.0.CO;2-0
  19. Hsing AW, Sakoda LC, Rashid A, et al (2008). Body size and the risk of biliary tract cancer: a population-based study in China. Br J Cancer, 99, 811-5. https://doi.org/10.1038/sj.bjc.6604616
  20. Jaiswal M, LaRusso NF, Burgart LJ, et al (2000). Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res, 60, 184-90.
  21. Khan SA, Toledano MB, Taylor-Robinson SD (2008). Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford), 10, 77-82. https://doi.org/10.1080/13651820801992641
  22. Koga A, Ichimiya H, Yamaguchi K, et al (1985). Hepatolithiasis associated with cholangiocarcinoma. Possible etiologic significance. Cancer, 55, 2826-9. https://doi.org/10.1002/1097-0142(19850615)55:12<2826::AID-CNCR2820551219>3.0.CO;2-1
  23. Lee MY, Lin KD, Hsiao PJ, et al (2011). The association of diabetes mellitus with liver, colon, lung, and prostate cancer is independent of hypertension, hyperlipidemia, and gout in Taiwanese patients. Metabolism, 61, 242-9.
  24. Lee TY, Lee SS, Jung SW, et al (2008). Hepatitis B virus infection and intrahepatic cholangiocarcinoma in Korea: a case-control study. Am J Gastroenterol, 103, 1716-20. https://doi.org/10.1111/j.1572-0241.2008.01796.x
  25. Lepage C, Cottet V, Chauvenet M, et al (2011). Trends in the incidence and management of biliary tract cancer: a French population-based study. J Hepatol, 54, 306-10. https://doi.org/10.1016/j.jhep.2010.06.039
  26. Liu XF, Zou SQ, Qiu FZ (2003). Pathogenesis of cholangiocarcinoma in the porta hepatis and infection of hepatitis virus. Hepatobiliary Pancreat Dis Int, 2, 285-9.
  27. Matsuda T, Marugame T (2007). International comparisons of cumulative risk of gallbladder cancer and other biliary tract cancer, from Cancer Incidence in Five Continents Vol. VIII. Jpn J Clin Oncol, 37, 74-5. https://doi.org/10.1093/jjco/hyl158
  28. Michalaki V, Koutroulis G, Syrigos K, et al (2005). Evaluation of serum lipids and high-density lipoprotein subfractions (HDL2, HDL3) in postmenopausal patients with breast cancer. Mol Cell Biochem, 268, 19-24. https://doi.org/10.1007/s11010-005-2993-4
  29. Moerman CJ, Bueno-de-Mesquita HB (1999). The epidemiology of gallbladder cancer: lifestyle related risk factors and limited surgical possibilities for prevention. Hepatogastroenterology, 46, 1533-9.
  30. Nijhawan PK, Therneau TM, Dickson ER, et al (1999). Incidence of cancer in primary biliary cirrhosis: the Mayo experience. Hepatology, 29, 1396-8. https://doi.org/10.1002/hep.510290511
  31. Ohshima H, Tatemichi M, Sawa T (2003). Chemical basis of inflammation-induced carcinogenesis. Arch Biochem Biophys, 417, 3-11. https://doi.org/10.1016/S0003-9861(03)00283-2
  32. Park J, Tadlock L, Gores GJ, et al (1999). Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology, 30, 1128-33. https://doi.org/10.1002/hep.510300522
  33. Patel T (2001). Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology, 33, 1353-7. https://doi.org/10.1053/jhep.2001.25087
  34. Patel T (2006). Cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol, 3, 33-42. https://doi.org/10.1038/ncpgasthep0389
  35. Perumal V, Wang J, Thuluvath P, et al (2006). Hepatitis C and hepatitis B nucleic acids are present in intrahepatic cholangiocarcinomas from the United States. Hum Pathol, 37, 1211-6. https://doi.org/10.1016/j.humpath.2006.04.012
  36. Randi G, Franceschi S, La Vecchia C (2006). Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer, 118, 1591-602. https://doi.org/10.1002/ijc.21683
  37. Rashid A, Ueki T, Gao YT, et al (2002). K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China. Clin Cancer Res, 8, 3156-63.
  38. Reeves ME, DeMatteo RP (2000). Genes and viruses in hepatobiliary neoplasia. Semin Surg Oncol, 19, 84-93. https://doi.org/10.1002/1098-2388(200009)19:2<84::AID-SSU2>3.0.CO;2-0
  39. Sandoh N, Shirai Y, Hatakeyama K (1997). Incidence of anomalous union of the pancreaticobiliary ductal system in biliary cancer. Hepatogastroenterology, 44, 1580-3.
  40. Seccia M, Cavina E (1989). [Risk factors and etiopathogenesis of cancer of the gallbladder]. Ann Ital Chir, 60, 163-71; discussion 172.
  41. Shaib Y, El-Serag HB (2004). The epidemiology of cholangiocarcinoma. Semin Liver Dis, 24, 115-25. https://doi.org/10.1055/s-2004-828889
  42. Shaib YH, El-Serag HB, Davila JA, et al (2005). Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology, 128, 620-6. https://doi.org/10.1053/j.gastro.2004.12.048
  43. Shaib YH, El-Serag HB, Nooka AK, et al (2007). Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study. Am J Gastroenterol, 102, 1016-21. https://doi.org/10.1111/j.1572-0241.2007.01104.x
  44. Shebl FM, Andreotti G, Meyer TE, et al (2011). Metabolic syndrome and insulin resistance in relation to biliary tract cancer and stone risks: a population-based study in Shanghai, China. Br J Cancer, 105, 1424-9. https://doi.org/10.1038/bjc.2011.363
  45. Shebl FM, Andreotti G, Rashid A, et al (2010). Diabetes in relation to biliary tract cancer and stones: a population-based study in Shanghai, China. Br J Cancer, 103, 115-9. https://doi.org/10.1038/sj.bjc.6605706
  46. Shi JS, Zhou LS, Han Y, et al (2004). Expression of tumor necrosis factor and its receptor in gallstone and gallbladder carcinoma tissue. Hepatobiliary Pancreat Dis Int, 3, 448-52.
  47. Suzuki H, Li Y, Dong X, et al (2008). Effect of insulin-like growth factor gene polymorphisms alone or in interaction with diabetes on the risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev, 17, 3467-73. https://doi.org/10.1158/1055-9965.EPI-08-0514
  48. Tang ZY, Guo EQ, Yan HC, et al (2007). Risk factors for infectious morbidity in gallbladder cancer patients treated surgically. Hepatogastroenterology, 54, 22-7.
  49. Tao LY, He XD, Qu Q, et al (2010). Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a case-control study in China. Liver Int, 30, 215-21. https://doi.org/10.1111/j.1478-3231.2009.02149.x
  50. Tomimatsu M, Ishiguro N, Taniai M, et al (1993). Hepatitis C virus antibody in patients with primary liver cancer (hepatocellular carcinoma, cholangiocarcinoma, and combined hepatocellular-cholangiocarcinoma) in Japan. Cancer, 72, 683-8. https://doi.org/10.1002/1097-0142(19930801)72:3<683::AID-CNCR2820720310>3.0.CO;2-C
  51. Tyson GL, El-Serag HB(2011). Risk factors of cholangiocarcinoma. Hepatology, 54, 173-84
  52. Wells BJ, Mainous AG, 3rd, et al (2005). Iron, cholesterol, and the risk of cancer in an 18-year cohort. Asian Pac J Cancer Prev, 6, 505-9.
  53. Welzel TM, Graubard BI, El-Serag HB, et al (2007) Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol, 5, 1221-8. https://doi.org/10.1016/j.cgh.2007.05.020
  54. Welzel TM, McGlynn KA, Hsing AW, et al (2006). Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst, 98, 873-5. https://doi.org/10.1093/jnci/djj234
  55. Welzel TM, Mellemkjaer L, Gloria G, et al (2007). Risk factors for intrahepatic cholangiocarcinoma in a low-risk population: a nationwide case-control study. Int J Cancer, 120, 638-41. https://doi.org/10.1002/ijc.22283
  56. West J, Wood H, Logan RF, et al (2006). Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971-2001. Br J Cancer, 94, 1751-8. https://doi.org/10.1038/sj.bjc.6603127
  57. Wijaya I, Abdullah M (2011). Diagnosis and treatment update: cholangiocarcinoma. Acta Med Indones, 43, 212-5.
  58. Yamamoto S, Kubo S, Hai S, et al (2004). Hepatitis C virus infection as a likely etiology of intrahepatic cholangiocarcinoma. Cancer Sci, 95, 592-5. https://doi.org/10.1111/j.1349-7006.2004.tb02492.x
  59. Zhou HB, Wang H, Zhou DX, et al (2010). Etiological and clinicopathologic characteristics of intrahepatic cholangiocarcinoma in young patients. World J Gastroenterol, 16, 881-5.
  60. Zhou YM, Yin ZF, Yang JM, et al (2008). Risk factors for intrahepatic cholangiocarcinoma: a case-control study in China. World J Gastroenterol, 14, 632-5. https://doi.org/10.3748/wjg.14.632
  61. Zou S, Zhang L (2000). Relative risk factors analysis of 3,922 cases of gallbladder cancer. Zhonghua Wai Ke Za Zhi, 38, 805-8.

피인용 문헌

  1. Medical Risk Factors Associated with Cholangiocarcinoma in Taiwan: A Population-Based Case-Control Study vol.8, pp.7, 2013, https://doi.org/10.1371/journal.pone.0069981
  2. An Interleukin-6 Receptor Polymorphism is Associated with Opisthorchiasis-Linked Cholangiocarcinoma Risk in Thailand vol.15, pp.13, 2014, https://doi.org/10.7314/APJCP.2014.15.13.5443
  3. High Frequency of TP53 but not K-ras Gene Mutations in Bolivian Patients with Gallbladder Cancer vol.15, pp.13, 2014, https://doi.org/10.7314/APJCP.2014.15.13.5449
  4. Identification of Risk and Prognostic Factors for Patients with Clonorchiasis-Associated Intrahepatic Cholangiocarcinoma vol.21, pp.11, 2014, https://doi.org/10.1245/s10434-014-3710-x
  5. The Carcinogenic Liver Fluke Opisthorchis viverrini is a Reservoir for Species of Helicobacter vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.1751
  6. Type 2 diabetes mellitus and risk of gallbladder cancer: a systematic review and meta-analysis of observational studies vol.32, pp.1, 2015, https://doi.org/10.1002/dmrr.2671
  7. Prospective Study of Glycemic Load, Glycemic Index, and Carbohydrate Intake in Relation to Risk of Biliary Tract Cancer vol.111, pp.6, 2016, https://doi.org/10.1038/ajg.2016.101
  8. The influence of BMI on the association between serum lycopene and the metabolic syndrome vol.115, pp.07, 2016, https://doi.org/10.1017/S0007114516000179
  9. Biliary Microbiota, Gallstone Disease and Infection with Opisthorchis felineus vol.10, pp.7, 2016, https://doi.org/10.1371/journal.pntd.0004809
  10. Body Mass Index, Diabetes and Intrahepatic Cholangiocarcinoma Risk: The Liver Cancer Pooling Project and Meta-analysis pp.1572-0241, 2018, https://doi.org/10.1038/s41395-018-0207-4
  11. Association between metabolic syndrome and hepatobiliary cancers: A case-control study pp.0975-0711, 2019, https://doi.org/10.1007/s12664-018-0925-y